# US 2021/0079005 A1 · Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079005 A1
- Document ID: US20210079005A1
- Status: Published application
- Kind: A1
- Application number: 17/105,060
- Filed: 2020-11-25
- Published: 2021-03-18
- Earliest claimed: 2018-06-29
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Martin Duplessis; Annick Goergler; Georg Jaeschke; Buelent Kocer; Bernd Kuhn; Kiel Lazarski; Yanke Liang; Yvonne Alice Nagel; Ulrike Obst Sander; Antonio Ricci; Daniel Rueher; Sandra Steiner
- Web page: https://patentgrep.com/patent/US20210079005A1

## CPC

- C07D 471/14: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- A61K 9/00: Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/02: Suppositories; Bougies; Bases therefor; {Ovules}(apparatus for making A61J3/08; devices for introducing into the body A61M31/00)
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61K 9/485: {Inorganic compounds}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 9/4875: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/4858)}
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/38: Cellulose; Derivatives thereof
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides compounds which are selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.

## Claims

### Claim 1

A compound of formula I,
wherein
L is absent or —(C≡C)—,
A is
B is aryl or heteroaryl,
C is heteroaryl,
Y is N, C(OH) or CH,
R1 is each independently selected from the group consisting of
i) amino,
ii) C1-6-alkyl,
iii) C1-6-alkoxy,
iv) cyano,
v) halogen,
vi) halogen-C1-6-alkyl,
vii) halogen-C1-6-alkoxy, and
viii) hydroxy;
R2 is each independently selected from the group consisting of
i) —(CH2)k—N(R4,R5),
ii) —(C═O)—N(R4,R5),
iii) halogen,
iv) halogen-C1-6-alkyl,
v) —NH—(C═O)—C1-6-alkyl, and
vi) C1-6-alkyl, optionally substituted by OH;
R3 is each independently selected from the group consisting of
i) amino,
ii) C1-6-alkyl,
iii) C1-6-alkoxy,
iv) cyano,
v) halogen,
vi) halogen-C1-6-alkyl,
vii) halogen-C1-6-alkoxy, and
viii) hydroxy;
R4 is each independently selected from the group consisting of
i) H, and
ii) C1-6-alkyl;
R5 is each independently selected from the group consisting of
i) H,
ii) C1-6-alkyl, and
iii) —(C═O)—C1-6-alkyl;
or R4 and R5 form together with the N they are attached to a heterocyclyl, which heterocyclyl is optionally be substituted by one to three R6.
R6 is each independently selected from the group consisting of
i) —OH,
ii) halogen,
iii) C3-8-cycloalkyl,
iv) halogen-C1-6-alkyl,
v) C1-6-alkoxy-C1-6-alkyl,
vi) cyano-C1-6-alkyl,
vii) C1-6-alkyl, and
viii) —(C═O)—C1-6-alkyl;
R7 is each independently selected from the group consisting of
i) H,
ii) halogen,
iii) halogen-C1-6-alkoxy,
iv) C1-6-alkoxy, and
v) C1-6-alkyl;
R8 is each independently selected from the group consisting of
i) H,
ii) halogen,
iii) C1-6-alkoxy, and
iv) C1-6-alkyl;
R9 is each independently selected from the group consisting of
i) H,
ii) halogen,
iii) halogen-C1-6-alkoxy,
iv) C1-6-alkoxy, and
v) C1-6-alkyl;
k is 0, 1 or 2,
n is 0, 1, 2, 3 or 4;
m is 0, 1 or 2;
p is 0 or 1;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein
L is absent or —(C≡C)—,
A is
B is aryl or heteroaryl,
C is heteroaryl,
Y is N or CH,
R2 is each independently selected from the group consisting of
i) —(CH2)k—N(R4,R5),
ii) halogen-C1-6-alkyl, and
iii) C1-6-alkyl, optionally substituted by OH;
R4 and R5 form together with the N they are attached to a heterocyclyl, which heterocyclyl is optionally be substituted by one to three R6.
R6 is each independently selected from the group consisting of
i) —OH,
ii) halogen,
iii) C3-8-cycloalkyl,
iv) halogen-C1-6-alkyl,
v) C1-6-alkoxy-C1-6-alkyl,
vi) cyano-C1-6-alkyl, and
vii) C1-6-alkyl;
R7 is H or halogen;
R8 is H;
R9 is halogen;
k is 0 or 1;
n is 0;
m is 1;
p is 0.

### Claim 3 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein A is
wherein
Y is N or CH, and
Ra, Rb, Rc or Rd is each independently selected from the group consisting of
i) H,
ii) amino,
iii) C1-6-alkyl,
iv) C1-6-alkoxy,
v) cyano,
vi) halogen,
vii) halogen-C1-6-alkyl,
viii) halogen-C1-6-alkoxy, and
ix) hydroxyl.

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein A is

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein B is aryl.

### Claim 6 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein B is phenyl.

### Claim 7 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein B is heteroaryl.

### Claim 8 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein B is pyridinyl.

### Claim 9 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein C is pyridinyl.

### Claim 10 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein C is thiazolyl.

### Claim 11 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein n is 0.

### Claim 12 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 1.

### Claim 13 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein p is 0.

### Claim 14 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is —(CH2)k—N(R4,R5), k is 0 or 1 and R4 and R5 form together with the N they are attached to a heterocyclyl, which heterocyclyl is optionally substituted by R6.

### Claim 15 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is —(CH2)k—N(R4,R5), k is 0 or 1 and R4 and R5 form together with the N they are attached to piperazinyl, piperidinyl or morpholino, which piperazinyl, piperidinyl or morpholino are optionally substituted by R6.

### Claim 16 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of

### Claim 17 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, that is selected from the group consisting of

### Claim 18 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, according to claim 1, that is selected from the group consisting of

### Claim 19 (depends on 1)

A method of treating a disorder mediated by the epidermal growth factor receptor (EGFR) comprising administering a compound of claim 1, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the patient is a human.

### Claim 21 (depends on 20)

The method of claim 20, wherein the disorder is cancer.

### Claim 22 (depends on 21)

The method of claim 21, wherein the cancer is non-small-cell lung cancer.

### Claim 23 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable auxiliary substance.
